|Articles|July 1, 2020
- Pharmaceutical Executive-07-01-2020
- Volume 40
- Issue 7
Pharmaceutical Executive, July 2020 Issue (PDF)
Click the title above to open the Pharmaceutical Executive July 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 6 years ago
Will COVID-19 Usher in a New Era in Pharma Marketing?almost 6 years ago
Is Drug Production Heading Back to Europe From Abroad?almost 6 years ago
Central Focus: Targeting Unmet Need in CNSalmost 6 years ago
Will the Industry Rise to the Occasion?almost 6 years ago
How Oncologists are Coping with COVID-19almost 6 years ago
Virtual Hiring of the C-Suitealmost 6 years ago
Culture and Compliance: Building a Culture of Business Ethicsalmost 6 years ago
Fauci: Industry Will ‘Walk Away’ From COVID Price Controlsalmost 6 years ago
A Sustainable Response to COVID-19almost 6 years ago
Enterprise Leadership: Is Compliance Ripe for Disruption?Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Asembia ASX26: Adjusting Strategies to Adapt to an Uncertain Global Political and Regulatory Market
2
Which Supply Chains are Most Exposed by Disruptions in The Strait of Hormuz?
3
Teva Enters $900 Million Agreement to Acquire Emalex
4
Pharmaceutical Risks in the Strait of Hormuz
5
